Sotorasib (racemate)

Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].

Product Specifications

CAS Number

[2252403-56-6]

Product Name Alternative

AMG-510 (racemate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P38 MAPK; Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AMG-510_racemate.html

Purity

98.99

Solubility

DMSO : 3.85 mg/mL (ultrasonic)

Smiles

O=C1N(C2=C(C)C=CN=C2C(C)C)C3=NC(C4=C(O)C=CC=C4F)=C(F)C=C3C(N5[C@@H](C)CN(C(C=C)=O)CC5)=N1

Molecular Formula

C30H30F2N6O3

Molecular Weight

560.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Karen Rex, et al. Abstract 3090: In vivo characterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models. Experimental and Molecular Therapeutics.|[2]Beltran, P, et al. Combination therapy comprising substituted pyrimidin-4 (3H) -ones and sotorasib for treating cancer in subjects with KRAS gene mutations. International, WO 2023/056037 A1.2023-04-06.